## STE: STERIS plc - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -2.3% below STRENGTH zone (4.0-10.0%); PEG 1.75 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-4.4% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($250.88)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. Should You Hold STERIS Stock in Your Portfolio for Now?**
- Source: TradingView | 20251204T130854 | Neutral | Relevance: 100%
- STERIS plc (STE) is experiencing growth driven by its service revenues in Applied Sterilization Technologies (AST) and increased adoption in its Healthcare segment, with shares outperforming the industry and S&P 500. However, macroeconomic volatility and adverse currency fluctuations pose concerns for the company. Despite these challenges, positive investments in innovation and strong quarterly results suggest potential for continued growth.

**2. Should You Hold STERIS Stock in Your Portfolio for Now?**
- Source: The Globe and Mail | 20251204T150817 | Neutral | Relevance: 100%
- STERIS plc (STE) is exhibiting strong growth in its Applied Sterilization Technologies (AST) and Healthcare segments, driven by successful market adoption and increasing service revenues. Despite these positives, macroeconomic volatilities and adverse currency fluctuations pose concerns for the stock. The company has a Zacks Rank #3 (Hold) and has outperformed its industry and the S&P 500 over the past year.

**3. STERIS plc $STE Shares Purchased by Locust Wood Capital Advisers LLC**
- Source: MarketBeat | 20251204T130932 | Bullish | Relevance: 100%
- Locust Wood Capital Advisers LLC increased its holding in STERIS plc (NYSE:STE) by 12.4% during Q2, bringing its total to 416,588 shares, valued at approximately $100.1 million. STERIS reported strong Q-earnings, beating EPS and revenue expectations, and provided optimistic FY2026 guidance. The company also announced a quarterly dividend of $0.63 per share, while several insiders sold shares totaling approximately $6.62 million in the last three months.

**4. Hsbc Holdings PLC Sells 11,353 Shares of STERIS plc $STE**
- Source: MarketBeat | 20251204T113046 | Somewhat-Bullish | Relevance: 100%
- Hsbc Holdings PLC reduced its stake in STERIS plc by 21.9%, selling 11,353 shares and retaining 40,579 shares valued at $9.69 million. Institutional investors now own 94.69% of the stock, while insiders have offloaded 25,203 shares ($6.62 million) in the last three months, including sales by VP Julia Madsen and CEO Daniel Carestio. STERIS reported strong quarterly earnings, beat revenue estimates, guided a positive FY2026 EPS, announced a $0.63 quarterly dividend, and holds a "Moderate Buy" consensus rating with an average price target of $273.50.

**5. 1,135 Shares in STERIS plc $STE Acquired by Legacy Capital Wealth Partners LLC**
- Source: MarketBeat | 20251202T120155 | Somewhat-Bullish | Relevance: 100%
- Legacy Capital Wealth Partners LLC acquired a new stake of 1,135 shares in STERIS plc (NYSE:STE) during the second quarter, valued at approximately $273,000. This comes as other institutional investors also adjusted their holdings, with Norges Bank making a significant new investment of $289.1 million. STERIS reported strong Q2 earnings, beating analyst expectations for both EPS and revenue, and announced a quarterly dividend of $0.63 per share.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 11 ($0.79M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 46.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 12.4% (+0.4%)
- Blackrock Inc.: 8.9% (+1.3%)
- Massachusetts Financ: 4.9% (-7.7%)
- State Street Corpora: 4.4% (+4.0%)
- Morgan Stanley: 4.3% (+8.3%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-4.4% 5d) with bearish MACD, trend may be turning.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.75 elevated, pricing in significant growth expectations. Forward P/E 23.4x stretched relative to 9% growth. Balance sheet: strong liquidity (2.4x), low leverage (D/E 0.48). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $25.2B |
| Beta | 1.01 |
| 52W Range | $200.98 - $268.60 |
| Short Interest | 1.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.75 |
| Forward P/E | 23.4 |
| Current P/E | 25.6 |
| YoY Growth | 9.1% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 2.1% to -2.3% (-4.4% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 6.3pp (needs >4.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.10x) but short-term weakness (below SMA20). MACD histogram bearish (-0.75), momentum weakening. RSI neutral at 56. OFD pattern: +MTL (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -2.29% (CS: 30) | Weak |
| RSI_14 | 56.4 | Neutral |
| MACD Histogram | -0.75 | Bearish |
| vs SMA20 | 0.997x | Below |
| vs SMA50 | 1.047x | Above |
| vs SMA200 | 1.098x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $261.02
- **Stop Loss:** $250.88 (3.9% risk)
- **Target:** $271.16 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 49
- **Position Value:** $12,789.98
- **Portfolio %:** 12.79%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with moderate risk appetite and mixed signals. VIX at 15.78 indicates calm conditions but breadth at 53% suggests narrow participation. Fed policy remains neutral with 42 days to next meeting, supporting steady positioning with sector selectivity.*

### Earnings

**Next:** 2026-02-04 (Est: $2.53)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.35 | $2.47 | +5.1% |
| 2025Q2 | $2.26 | $2.34 | +3.4% |
| 2025Q1 | $2.60 | $2.74 | +5.4% |
| 2024Q4 | $2.32 | $2.32 | -0.1% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*